Press Release Source: Power3 Medical Products, Inc. On Tuesday, April 27, 2010, 6:49 pm EDT
HOUSTON–(BUSINESS WIRE)–StemTroniX, Inc., a Texas corporation (“StemTroniX”), and Power3 Medical Products, Inc. (OTCBB:PWRM – News) announced today that a plenary address entitled “The Genesis of Prototype Biomarkers for Identification and Use of Stem Cells for Therapeutics of Alzheimer’s Disease” will be delivered by Ira L. Goldknopf, PhD, Power3’s President and Chief Scientific Officer, to the European Molecular Histopathology Symposium on The Impact of Personalized Medicine, April 29, 2010, in Chantilly, France, organized by Ventana Medical Systems, a member of the Roche Group.
The focus of the presentation is on the progress Power3 and StemTroniX have made towards enhanced effectiveness of Alzheimer’s disease therapy by combining StemTroniX’s patented and patent pending adult stem cell regenerative medicine technologies with Power3’s patent pending blood serum adult stem cell protein biomarkers and diagnostic technologies. StemTroniX’s technologies include a licensed patent and several patent disclosures for monitoring of stem cell therapy, technology to aid in the viability of adult stem cells, injection technology, and non-invasive imaging technology. These technologies complement Power3’s technologies for Alzheimer’s specific diagnosis, multiple forms of Alzheimer’s disease, response to Alzheimer’s drug therapy, predictive drug response, and discovery of more clinically relevant tissue, blood and adult stem cell biomarkers.
“Biomarkers for the support of autologous (a patient’s own) stem cell therapies of Alzheimer’s disease are needed to light the way to true recovery, i.e. to the restoration of the patient through repair and regeneration of the brain tissue ravaged by the disease. Nothing less is acceptable for true regenerative medicine,” said Goldknopf. “To achieve these ends, we believe it is necessary to set the bar high, so that we can find biomarkers related to the restoration of normality, not only with respect to symptoms, but also with respect to correcting the underlying and devastating pathophysiology of Alzheimer’s disease. We will demonstrate steps already taken towards this goal as well as illustrate essential requirements for the way forward.”
“In conjunction with the upcoming acquisition of StemTroniX by Power3, and recent patent filings, this presentation marks a significant step towards the joint goal of StemTroniX and Power3, to fulfill the promise of personalized medicine by providing desperately needed diagnosis and targeted therapy for Alzheimer’s disease,” said Helen R. Park, StemTroniX’s CEO.
Power3 Medical Products
Power3 Medical Products, Inc. is a leader in bio-medical research and the commercialization of biomarkers, tests, and mechanisms of disease. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, to fulfill critical unmet needs in areas including neurodegenerative disease (NuroPro®) and breast cancer (BC-SeraPro™). Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, breast cancer, and drug resistance.
For more information, please visit http://www.power3medical.com
StemTroniX, Inc. is a medical biotechnology company that is committed to improving the lives of individuals by using autologous adult stem cell technology to repair tissue damage in patients. Autologous adult stem cell therapy is the process of using an individual’s own stem cells for the purpose of repairing and regenerating damaged tissue. StemTroniX also provides a patented system to augment this process in a non-invasive method for in-body monitoring of the stem cells at the site of injury as they are being introduced into the patients.